Trimetrexate

Trimetrexate

SCHEMBL28166138

COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC.O=C(O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.O=P(O)(O)O

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Trimetrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 1/20 0.66
KCNH2 known ✓ Q12809 1/20 0.66
DHFR P00374 9/20 0.66
MEN1 O00255 1/20 0.66
ALDH1A1 P00352 1/20 0.66
ESR1 P03372 1/20 0.66
CHRM2 P08172 1/20 0.66
HTR1A P08908 1/20 0.66
MAPT P10636 1/20 0.66
CHRM1 P11229 1/20 0.66
HPGD P15428 1/20 0.66
MAOA P21397 1/20 0.66
DRD1 P21728 1/20 0.66
ACHE P22303 1/20 0.66
PTGS1 P23219 1/20 0.66
SLC6A2 P23975 1/20 0.66
PDE4A P27815 1/20 0.66
DRD3 P35462 1/20 0.66
BLM P54132 1/20 0.66
SLC6A3 Q01959 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trimetrexate SCHEMBL29572854 0.97 DHFR (0.70) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL28151291 0.97 DHFR (0.70) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL28146995 0.89 DHFR (0.68) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL28142980 0.86 DHFR (0.88) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL7099424 0.83 DHFR (0.88) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL7099127 0.82 DHFR (0.86) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL29376841 0.81 DHFR (1.00) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL10701228 0.81 DHFR (1.00) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL3983 0.81 DHFR (1.00) DHFRMEN1ALDH1A1ESR1CHRM2
Trimetrexate SCHEMBL29403928 0.81 DHFR (1.00) DHFRMEN1ALDH1A1ESR1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109952309-A CONSTITUTIVELY ACTIVE CYTOKINE RECEPTORS FOR CELL THERAPY 贝勒医学院 2019-06-28 CN disclosed
CN-109715174-A Method and composition for T cell immunization therapy 埃图比克斯公司 2019-05-03 CN disclosed
CN-109196103-A The 3D RNA cage type nanoparticle of self assembly 俄亥俄州立创新基金会 2019-01-11 CN disclosed
CN-107406857-A Methods and compositions for combination immunotherapy 埃图比克斯公司 2017-11-28 CN disclosed
CN-107405321-A Use of short chain fatty acids in cancer prevention 坦普尔大学 2017-11-28 CN disclosed
CN-107073122-A The therapeutic alliance of malignant tumour 细胞基因公司 2017-08-18 CN disclosed